地诺孕素治疗复发型卵巢子宫内膜异位症的临床效果

Abstract
Figure/Table
References (15)
Related Citation (15)

Download: PDF (0 KB) HTML (34 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective To explore the clinical efficacy of Dienogest in the treatment of recurrent ovarian endometriosis(OEM).Methods A total of 40 patients with recurrent OEM admitted to Jiangxi Maternity and Child Health Hospital from September 2019 to March 2020 were selected as the research objects and divided into the control group and the observation group by random number table method, with 20 cases in each group.Patients in the control group were treated with Drospirenone Ethinyl Estradiol Tablets, and in the observation group, patients were treated with Dienogest.The menstruation, endometriotic cyst volume, dysmenorrhea, chronic pelvic pain or dyspareunia visual analogue scale(VAS) score, serum carbohydrate antigen 125 (CA125), blood lipid levels and the incidence of adverse reactions were compared between the two groups before treatment and 3 and 6 months after treatment.Results There were no statistically significant differences in the rate of normal menstrual frequency and normal menstrual period between the two groups after treatment (P＞0.05).There were no statistically significant differences in volume of cysts, VAS score of dysmenorrhea, VAS score of pelvic pain or dyspareunia, serum CA125, triglyceride and total cholesterol between the two groups before treatment (P＞0.05).After 6 months of treatment, the volume of cysts in the observation group was lower than that in the control group, VAS score of dysmenorrhea, VAS score of pelvic pain or dyspareunia and serum CA125 in the observation group were lower than those in the control group, and the differences were statistically significant (P＜0.05).There were no statistically significant differences in triglyceride, total cholesterol and clinical adverse reactions between the two groups after six months of treatment (P＞0.05).Conclusion Dienogest can significantly relieve pain, reduce the volume of cysts and serum CA125 in OEM patients, and the clinical effect is good.

Key words： Dienogest Ovarian endometriosis Curative effect

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors

Cite this article:

URL:

http://dangdaiyiyao.com/EN/ OR http://dangdaiyiyao.com/EN/Y2021/V28/I20/118

[1]	王敏，潘月，罗汝琼.GnRH-a 联合腹腔镜手术治疗卵巢子宫内膜异位症的疗效及对卵巢储备功能的影响[J].中国妇幼保健，2018，33（8）：68-70.
[2]	操丽，李伟莉.中医对子宫内膜异位症相关不孕症研究进展[J].中医药临床杂志，2018，30（4）：37-39.
[3]	苏亚璞.腹腔镜卵巢子宫内膜异位症囊肿剥除术中不同止血方法对患者卵巢储备功能的影响[J].河南医学研究，2018，27（3）：466-467.
[4]	中华医学会妇产科分会子宫内膜异位症协作组.子宫内膜异位症的诊治指南[J].中华妇产科杂志，2015，50（3）：161-169.
[5]	于传鑫.实用妇科内分泌学[M].上海：复旦大学出版社，2004：157-158.
[6]	严广斌.视觉模拟评分法[J].中华关节外科杂志（电子版），2014，8（2）：273.
[7]	潘淑芬，吴洁丽.子宫内膜异位症保守手术治疗后远期复发分析[J].浙江临床医学，2018，20（1）：52-54.
[9]	杨柳，赵仁峰，许莉莉，等.戊酸雌二醇地诺孕素治疗月经过多患者的疗效及安全性研究[J].中国临床新医学，2020，13（2）：146-149.
[10]	杨柳，赵仁峰．戊酸雌二醇联合地诺孕素治疗对月经过多患者激素水平的影响[J].广西医学，2019，41（13）：1704-1705，1709.
[11]	叶丹.高剂量地诺孕素治疗子宫内膜异位症的疗效及安全性评价[J].黑龙江医药，2016，29（3）：462-463.
[12]	刘小媚.评价高剂量地诺孕素治疗子宫内膜异位症的疗效及安全性[J].白求恩医学杂志，2016，14（4）：456-458.
[13]	毕小慧，黎少琴.中西医联合方案治疗子宫内膜异位症的疗效[J].深圳中西医结合杂志，2020，30（14）：39-40.
[14]	刘晓娟.高剂量地诺孕素治疗子宫内膜异位症疗效观察[J].河北北方学院学报（自然科学版），2017，33（4）：33-34，36.
[15]	王曼，陈龙.桂莪棱乌汤联合地诺孕素治疗子宫内膜异位症的疗效及对血清CA125 水平的影响[J].现代中西医结合杂志，2019，28（20）：2244-2246，2260.